RAD51 and thyroid gland carcinoma: For example, in thyroid carcinoma (THCA), 33 out of 128 (25.7%) patients in the RAD51 high group were predicted to respond to ICB treatment, while 42 out of 128 (32.8%) patients in the RAD51 low group were predicted to respond to ICB treatment.